Table 2.
Association between Baseline Warfarin Use and Baseline Bone Mineral Density (BMD)
| Age and Clinical Site-Adjusted | Multivariate Adjusted* | |||||||
|---|---|---|---|---|---|---|---|---|
| Skeletal Site |
Warfarin Nonusers (mean ± SE) |
Warfarin Users (mean ± SE) |
Mean Difference† (95% CI) |
P- value |
Warfarin Nonusers (mean ± SE) |
Warfarin Users (mean ± SE) |
Mean Difference† (95% CI) |
P- value |
| Total Hip BMD (g/cm2) |
0.959 ± 0.002 | 0.966 ± 0.008 | 0.007 (−0.008 to 0.023) |
0.37 | 0.959 ± 0.002 | 0.963 ± 0.008 | 0.004 (−0.012 to 0.019) |
0.64 |
| Total Spine BMD (g/cm2) |
1.074 ± 0.003 | 1.079 ± 0.010 | 0.005 (−0.016 to 0.026) |
0.64 | 1.074 ± 0.003 | 1.073 ± 0.011 | 0.001 (−0.023 to 0.020) |
0.90 |
*
Adjusted for age, race, site, hypertension, cardiovascular disease, 2 or more falls in the past year, self-reported health, and use of diuretics and beta-blockers.
†
Negative differences indicate lower BMD in Warfarin users group.